IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals
March 26 2020 - 8:30PM
Business Wire
India Globalization Capital, Inc. (the “Company”) (NYSE: IGC)
recently received notification that on March 24, 2020, the United
States Patent and Trademark Office (“USPTO”) issued a method and
composition patent (#10,596,159 B2) for the Company’s cannabinoid
formulation for the treatment of cachexia and eating disorders in
humans and veterinary animals. IGC filed this application for its
IGC-504 formulation (#15/751,901) on August 11, 2016. A public copy
of the patent is available on the USPTO website.
A patent for an invention is the grant of a property right to
the inventor, issued by the USPTO. Generally, the term of a new
patent is 20 years from the date on which the application for the
patent was filed in the United States or, in special cases, from
the date an earlier related application was filed, subject to the
payment of maintenance fees. U.S. patent grants are effective only
within the United States, U.S. territories, and U.S.
possessions.
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on IGC’s
expectations and are subject to a number of risks and
uncertainties, certain of which are beyond IGC’s control. Actual
results could differ materially from these forward-looking
statements as a result of, among other factors, worsening of the
COVID-19 outbreak in China, the U.S., and other parts of the world,
the prolonged continuation of travel restrictions related to the
outbreak, continued disruption of the Hong Kong economy,
competitive conditions in the industries in which IGC operates,
failure to meet operational goals and/or revenue and profit targets
of products in various stages of production and commercialization,
failure to commercialize one or more of the products or
technologies of IGC, including any products or patented
formulations identified herein, any changes in federal, state, or
local law applicable to our businesses and the locations where we
operate, general economic, political, and health and welfare
conditions that are less favorable than expected, the Federal Food
and Drug Administration’s (FDA) general position regarding
hemp-based and related products in particular, and other factors,
many of which are discussed in our SEC filings. The Risk Factors
identified in the Company’s annual report, filed on Form 10-K with
the SEC on June 14, 2019, and in the Company’s quarterly reports,
filed on Form 10-Q with the SEC on November 5, 2019 and February
10, 2020, are incorporated herein by reference. In light of these
risks and uncertainties, there can be no assurance that the
forward-looking information contained in this release will in fact
occur.
About IGC:
IGC has two lines of business: infrastructure and hemp-derived
medical cannabis/industrial hemp. The company is based in Maryland,
U.S.A. Our website: www.igcinc.us.Twitter @IGCIR
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200326005803/en/
Claudia Grimaldi 301-983-0998
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Aug 2024 to Sep 2024
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Sep 2023 to Sep 2024